Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Uroplasty has presented positive results from the OrBIT trial of its Urgent PC System. The results confirm that Urgent PC's PTNS reduces the incidence of voiding episodes at a rate comparable to tolterodine LA, known by the trade name Detrol LA, the leading pharmaceutical therapy for overactive bladder.
Subscribe to our email newsletter
The study results show that – 80% of percutaneous tibial nerve stimulation (PTNS) patients considered themselves cured or improved, while 55% of tolterodine LA patients considered themselves cured or improved. Physicians considered 80% of PTNS patients cured or improved, compared with 61% of tolterodine LA patients. The frequency of voiding episodes was reduced in 73% of PTNS patients versus 74% of tolterodine LA patients.
The Urgent PC System is a proprietary, minimally invasive percutaneous tibial nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence, symptoms often associated with overactive bladder.
Dave Kaysen, president and CEO of Uroplasty, said: “These results demonstrate that the Urgent PC is an effective and viable non-drug option for treating the urinary symptoms often associated with overactive bladder.”